The Latest Breaking News on Pharma

The drug store industry is well positioned for long-term growth thanks to the growing demand for prescription drugs. Let’s compare CVS Health (CVS) and MedAvail (MDVL) in this space to determine which is better positioned to capitalize on the industry’s solid growth prospects….

"Whilst the national report looked pretty daunting I’ve not found anything for significant cause for concern"

THE UK’S response to the Covid pandemic has been branded “colonial” and “fuelled by nationalism” by justice campaigners.

Funding for drug treatment centers in Oregon, financed by the state’s pioneering drug decriminalization policy, stands these days at over a quarter-billion dollars

Morris & Dickson Co.'s license has been revoked by the US Drug Enforcement Administration (DEA) following a 68-page order by DEA Administrator Anne Milgram on the opioid crisis

The agency says it will strip Morris & Dickson of its license to sell highly addictive painkillers after finding it failed to flag thousands of suspicious orders at the height of the opioid crisis.

The U.S. Drug Enforcement Administration has stripped one of the nation’s largest pharmaceutical distributors of its license to sell highly addictive painkillers after determining it failed to flag thousands of suspicious, high-volume orders at the height of the opioid crisis

Banks Bourne, sole owner of Tanner Pharma in North Carolina, took sum from Tanner’s UK arm, records show

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore, investors could look to avoid fundamentally weak biotech stocks Bicycle Therapeutics (BCYC), CorMedix (CRMD), and 22nd Century Group (XXII).…

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.